Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry.  Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology.

PCCs routinely demonstrate single amino acid specificity and sub nanomolar affinities with the size (< 4 kD) and pharmacological properties of small molecules. They are also easily and rapidly modified using conventional medicinal chemistry. The PCC platform allows us to build fully synthetic small peptides against specific epitopes of the desired target protein.

SPECIFICITY

Specific to the chosen epitope of the desired target protein

Affinity

Pico-molar and low nano-molar binding affinities with demonstrable cooperative binding for affinity enhancement

Tunable

Fully synthetic small peptides for rapid synthesis and robust manufacturing

SPEED

Go from an identified epitope to nanomolar binding affinity in 4 weeks

IN VIVO

PCC have demonstrated in vivo functional activity

Recent News